Stocks and Investing Stocks and Investing
Fri, June 24, 2022
Thu, June 23, 2022
Wed, June 22, 2022
Tue, June 21, 2022

Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $26 on, Jun 21st, 2022


Published on 2024-10-27 21:33:46 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $32 to $26 on, Jun 21st, 2022.

Gregory has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Gregory


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022